EE9900573A - Kristalliline roksifibaan - Google Patents

Kristalliline roksifibaan

Info

Publication number
EE9900573A
EE9900573A EEP199900573A EEP9900573A EE9900573A EE 9900573 A EE9900573 A EE 9900573A EE P199900573 A EEP199900573 A EE P199900573A EE P9900573 A EEP9900573 A EE P9900573A EE 9900573 A EE9900573 A EE 9900573A
Authority
EE
Estonia
Prior art keywords
crystalline roxifiban
roxifiban
crystalline
Prior art date
Application number
EEP199900573A
Other languages
English (en)
Inventor
B. Maurin Michael
Ma Philip
J. Meloni David
A. Pesti Jaan
T. Rossano Lucius
K. Ward Randall
Yin Jianguo
Zhang Lin-Hua
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE9900573A publication Critical patent/EE9900573A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP199900573A 1997-06-16 1998-06-12 Kristalliline roksifibaan EE9900573A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4963397P 1997-06-16 1997-06-16
US4971297P 1997-06-16 1997-06-16
US8027898P 1998-04-01 1998-04-01
PCT/US1998/012367 WO1998057939A1 (en) 1997-06-16 1998-06-12 Crystalline roxifiban

Publications (1)

Publication Number Publication Date
EE9900573A true EE9900573A (et) 2000-08-15

Family

ID=27367578

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900573A EE9900573A (et) 1997-06-16 1998-06-12 Kristalliline roksifibaan

Country Status (18)

Country Link
US (1) US6306886B1 (et)
EP (1) EP0991630A1 (et)
JP (1) JP2002504153A (et)
KR (1) KR20010013790A (et)
CN (1) CN1259940A (et)
AR (2) AR016070A1 (et)
AU (1) AU751198B2 (et)
CA (1) CA2294047A1 (et)
EA (1) EA200000028A1 (et)
EE (1) EE9900573A (et)
HR (1) HRP980291A2 (et)
HU (1) HUP0004755A3 (et)
IL (1) IL132618A0 (et)
NO (1) NO996182D0 (et)
NZ (1) NZ502077A (et)
PL (1) PL337612A1 (et)
SK (1) SK166699A3 (et)
WO (1) WO1998057939A1 (et)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
MA34247B1 (fr) * 2010-05-27 2013-05-02 Du Pont Forme cristalline du 4-[5-[3-chloro-5-(trifluorométhyl) phényl] -4,5-dihydro-5-(trifluorométhyl)-3-isoxazolyl]-n-[2-oxo-2-[(2, 2,2-trifluoroéthyl) amino] éthyl]-1-naphtalènecarboxamide
CN103534584B (zh) * 2011-05-17 2016-05-04 齐塔库比有限责任公司 使用同步辐射检测多晶型物的方法
GB2515783B (en) * 2013-07-03 2018-07-11 Rotam Agrochem Int Co Ltd Process for preparing clomazone, a form and use of the same
KR20240037628A (ko) 2022-09-15 2024-03-22 문혜경 그래핀이 함유된 고강도 내열 안경렌즈 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ276633A (en) * 1993-11-24 1998-04-27 Du Pont Merck Pharma Isoxazole and isoxazoline derivatives and pharmaceutical compositions thereof
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists

Also Published As

Publication number Publication date
NO996182L (no) 1999-12-14
AU8071998A (en) 1999-01-04
NZ502077A (en) 2002-03-01
AR023840A2 (es) 2002-09-04
NO996182D0 (no) 1999-12-14
CA2294047A1 (en) 1998-12-23
CN1259940A (zh) 2000-07-12
AU751198B2 (en) 2002-08-08
JP2002504153A (ja) 2002-02-05
HUP0004755A3 (en) 2002-10-28
HUP0004755A2 (hu) 2001-07-30
HRP980291A2 (en) 1999-04-30
SK166699A3 (en) 2001-09-11
AR016070A1 (es) 2001-06-20
EA200000028A1 (ru) 2000-08-28
PL337612A1 (en) 2000-08-28
US6306886B1 (en) 2001-10-23
IL132618A0 (en) 2001-03-19
KR20010013790A (ko) 2001-02-26
EP0991630A1 (en) 2000-04-12
WO1998057939A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
NO20003131D0 (no) Krystallinsk teriparatid
DK0973746T3 (da) Substituerede 3-cyanoquinoliner
ATE233060T1 (de) Zahnbürste
ATE537728T1 (de) Zahnbürste
DE69815089D1 (de) Selbstaufrichtende zahnbürste
DE69810911D1 (de) Zahnbürste
NO994433D0 (no) InnÕndingsanordning
DE59806063D1 (de) Zahnbürste
EP0953464A4 (en) LOUVRE
DE59813487D1 (de) Substituierte 4-benzoyl-pyrazole
DE69714228D1 (de) Kristalline metallophosphate
DE69809270D1 (de) Zahnbürste
NO996182D0 (no) Krystallinsk roksifiban
DK0960100T3 (da) Substituerede 4-benzoyl-pyrazoler
DE69614821D1 (de) Geschalteter Taktgeber
KR980000103U (ko) 자라사육기
DE59807877D1 (de) Substituierte 4-benzoyl-pyrazole
ID24079A (id) Aminoheteroksiklilamida tersubstitusi
NO983650D0 (no) Krystallinske progestagener
DE59810960D1 (de) Substituierte phenyluracile
KR980000415U (ko) 치솔
DE59811399D1 (de) Substituierte phenyluracile
KR980000413U (ko) 칫솔
SE9702294D0 (sv) Tandborste
ATA211597A (de) Zahnbürste